Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lurasidone in adolescents and adults with schizophrenia: from clinical trials to real-world clinical practice
Andrea Fiorillo, Alessandro Cuomo, Gaia Sampogna, et al.
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 16, pp. 1801-1818
Open Access | Times Cited: 10

Showing 10 citing articles:

Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy
Itaru Miura, Sho Horikoshi, Mizue Ichinose, et al.
Drug Design Development and Therapy (2023) Vol. Volume 17, pp. 3023-3031
Open Access | Times Cited: 13
Microneedle-Assisted Transdermal Delivery of Lurasidone Nanoparticles
Ariana Radmard, Ajay K. Banga
Pharmaceutics (2024) Vol. 16, Iss. 3, pp. 308-308
Open Access | Times Cited: 4
The Role of Lurasidone in Managing Depressive Symptoms in People with Schizophrenia: A Review
Andrea Fiorillo, Gaia Sampogna, Umberto Albert, et al.
Brain Sciences (2024) Vol. 14, Iss. 3, pp. 225-225
Open Access | Times Cited: 4
Efficacy of Lurasidone in First-Episode Psychosis: Patient Phenotypes, Dosage, and Recommendations from an Expert Panel
Miquel Bernardo, Marina Dı́az-Marsá, Ana González‐Pinto, et al.
Neurology and Therapy (2025)
Open Access
Lurasidone uses and dosages in Spain: RETROLUR, a real-world retrospective analysis using artificial intelligence
F. Mora, Carlos Gómez Sánchez-Lafuente, Mariano de Iceta Ibáñez de Gauna, et al.
Frontiers in Psychiatry (2025) Vol. 15
Open Access
Genetic markers of early response to lurasidone in acute schizophrenia
Akane Yoshikawa, Jiang Li, Ney Alliey‐Rodriguez, et al.
The Pharmacogenomics Journal (2025) Vol. 25, Iss. 2
Open Access
Identification of lurasidone as a potent inhibitor of severe fever with thrombocytopenia syndrome virus by targeting the viral nucleoprotein
Ting Cheng, Qingcui Xiao, Jing Cui, et al.
Frontiers in Microbiology (2025) Vol. 16
Open Access
Towards full recovery with lurasidone: effective doses in the treatment of agitation, affective, positive and cognitive symptoms in schizophrenia, and dual psychosis
María Teresa Carreras, Luis Jiménez Suárez, Laura Lago García, et al.
Drugs in Context (2024) Vol. 13, pp. 1-18
Open Access | Times Cited: 3
Rash caused by lurasidone in old chinese patient with bipolar disorder: case-based review
Wenjuan Yang, Danhong Hu, Bei Zheng, et al.
BMC Psychiatry (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Brexpiprazole-Induced Hyperprolactinemia in Patient With Pituitary Gland Tumor
Thomas Prates Ong, Wan‐Ting Chen, Yi‐Wei Yeh, et al.
American Journal of Therapeutics (2024)
Closed Access | Times Cited: 1
Correlation analyse between thyroid hormone levels and severity of schizophrenia symptoms
Qin Jiang, Weidong Gong
World Journal of Psychiatry (2024) Vol. 15, Iss. 1
Closed Access
Page 1

Scroll to top